Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is an increasingly common chronic respiratory condition that remains underrecognized and underprioritized globally. Affected persons commonly undergo prolonged symptoms, delayed diagnosis, and lengthy multidrug treatments with significant toxicity and limited effectiveness. Despite rising incidence and mortality, particularly among older adults and those with structural lung disease, NTM-PD remains non-notifiable in most regions, resulting in major gaps in surveillance and care. Fragmented health-system responses, limited diagnostic capacity, and minimal therapeutic innovation contribute to neglect. Addressing NTM-PD requires improved surveillance, dedicated care pathways, and greater investment in patient-centered research and treatment.

More information Original publication

DOI

10.11565/arsmed.v51i2.2230

Type

Journal article

Publisher

Chimera Innova Group

Publication Date

2026-06-30T00:00:00+00:00

Volume

51

Pages

8 - 10

Total pages

2